Patients with nonvalvular atrial fibrillation who were prescribed apixaban vs rivaroxaban had a lower rate of ischemic stroke or systemic embolism and bleeding.
The setting of a target low-density lipoprotein cholesterol level below 70 mg/dL in the 5 years following an ischemic stroke was associated with a 25% reduction in intracranial hemorrhages.
The combination of higher serum oxidized low-density lipoprotein (oxLDL) and LDL levels was found to be associated with an increased risk for recurrent stroke and poor functional outcomes in patients who have had minor stroke or are at high risk for transient ischemic attacks.
Treatment with vorapaxar was associated with reductions in major adverse cardiovascular events and major adverse limb events in patients with peripheral artery disease and concomitant coronary artery disease.
Among hemodialysis patients with atrial fibrillation, racial/ethnic disparities in all-cause stroke are partially mediated by lower anticoagulant use.
Metabolic syndrome, including hypertension, obesity, dyslipidemia, and hyperglycemia, promote arterial stiffness, which has been linked to depression.
The CHASE-LESS score may be useful in identifying the risk for atrial fibrillation in patients hospitalized for ischemic stroke.
Discontinuation of vitamin K antagonist oral anticoagulant therapy was associated with an elevated risk for stroke or transient ischemic attack in patients newly diagnosed with nonvalvular atrial fibrillation.
The duration of carotid blood flow reversal during transcarotid artery revascularization for carotid bifurcation stenosis was not found to affect the rate of stroke, myocardial infarction, or death.
The risk for a cardiac event was found to be greater in patients with peripheral artery disease vs coronary artery disease.
